In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response
Fig 9
Survival curves of B16 melanoma-bearing mice after CpG/ CpG-construct treatment.
Injection of 1x10^6 B16 melanoma cells s.c., repetitive treatment (daily) with CpG/ CpG-scrambled RNA/ CpG-siRNA A20. (A) Treatment started on day 7 until end of experiment on day 14 (tumor diameter ≥10 mm). (B) Treatment started on day 4 until day 10. Shown is percentage of surviving mice till the end of the experiment (tumor diameter ≥10 mm).